Figure 2 | Scientific Reports

Figure 2

From: Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

Figure 2

Estimated overall survival in patients with locally advanced/MBC with liver (a) and lung (b) metastases at baseline (pooled population). (a) Patients with baseline liver metastases randomized to eribulin had a nominally significant difference in overall survival compared with patients randomized to TPC/capecitabine. (b) Patients with baseline lung metastases randomized to eribulin had no significant difference in overall survival compared to control. Control includes TPC and capecitabine; HR values and 2-sided 95% CIs were computed using Cox models with treatment as a covariate and stratified by study, region, prior capecitabine use, and HER2/neu status; nominal P values were based on log-rank tests and stratified as noted above. Medians were based on survival curves adjusted by study. CI, confidence interval; HR, hazard ratio; MBC, metastatic breast cancer; TPC, treatment of physician’s choice.

Back to article page